Issue 30, 2012

Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy

Abstract

Photodynamic therapy (PDT) has shown promise as an effective treatment modality for cancers and other localized diseases, such as age-related macular degeneration and actinic keratosis. PDT relies on light, photosensitizer and oxygen as elements in its mechanism of action. BODIPY photosensitizers that have been under extensive study over the past decade have been demonstrated as a new class of photosensitizers. In this review, we attempt to summarize the decade-long study of BODIPY-based photosensitizers. We provide an overview of the superior photophysical properties possessed by BODIPY-based agents and the various synthetic strategies employed that have led to improved and selective and/or targeted photosensitizers.

Graphical abstract: Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy

Supplementary files

Article information

Article type
Review Article
Submitted
09 Jul 2012
Accepted
06 Sep 2012
First published
07 Sep 2012

RSC Adv., 2012,2, 11169-11183

Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy

S. G. Awuah and Y. You, RSC Adv., 2012, 2, 11169 DOI: 10.1039/C2RA21404K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements